{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["147(1)"],"submitter":["Hirsch D"],"funding":["Medizinische Fakultät Mannheim, Universität Heidelberg"],"pubmed_abstract":["<h4>Purpose</h4>Immune checkpoint inhibitors have shown efficacy in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) gastrointestinal (GI) cancers. However, depth and duration of clinical response is not uniform. We assessed tumor mutation burden (TMB) as a response marker in patients with GI cancers treated with immune checkpoint inhibitors.<h4>Methods</h4>Detailed clinical and response data were collected from six patients with metastatic MSI-H/dMMR GI cancers treated with immune checkpoint inhibitors. Efficacy was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Tumors and matched normal tissue were profiled by targeted next generation sequencing (127 gene panel, size 0.8 Mb). Impact of included mutation types, germline f"],"journal":["Journal of cancer research and clinical oncology"],"pagination":["263-273"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7810640"],"repository":["biostudies-literature"],"pubmed_title":["Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system."],"pmcid":["PMC7810640"],"pubmed_authors":["Merx K","Hendricks A","Woenckhaus M","Gencer D","Hirsch D","Gaiser T","Hofheinz RD","Forster M","Weingaertner S","Schubert T"],"additional_accession":[]},"is_claimable":false,"name":"Clinical responses to PD-1 inhibition and their molecular characterization in six patients with mismatch repair-deficient metastatic cancer of the digestive system.","description":"<h4>Purpose</h4>Immune checkpoint inhibitors have shown efficacy in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) gastrointestinal (GI) cancers. However, depth and duration of clinical response is not uniform. We assessed tumor mutation burden (TMB) as a response marker in patients with GI cancers treated with immune checkpoint inhibitors.<h4>Methods</h4>Detailed clinical and response data were collected from six patients with metastatic MSI-H/dMMR GI cancers treated with immune checkpoint inhibitors. Efficacy was assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Tumors and matched normal tissue were profiled by targeted next generation sequencing (127 gene panel, size 0.8 Mb). Impact of included mutation types, germline f","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jan","modification":"2025-04-26T05:10:52.695Z","creation":"2021-02-21T01:53:09Z"},"accession":"S-EPMC7810640","cross_references":{"pubmed":["32776177"],"doi":["10.1007/s00432-020-03335-2"]}}